Founded in Berkeley, California, Biomedican is a biotechnology startup focused on synthetic biology and cellular agriculture. Their core mission is to commercialize disruptive intellectual property in emerging industries. Biomedican specializes in the organic biosynthesis of rare cannabinoids and high-value compounds, offering products such as CBG/CBGA, CBN/CBNA, THCA, and THCV/THCVA. The company aims to innovate and lead in the field of cannabinoid synthesis and research.
Biomedican has assembled a global team of experts to drive their research and development efforts. Notable achievements include the successful biosynthesis of rare cannabinoids, positioning the company as a leader in this niche market. Their work has significant implications for the pharmaceutical, wellness, and agricultural sectors, contributing to advancements in health and sustainability. The company's impact is underscored by its commitment to naturally grown, high-value compounds, setting new standards in biotechnology.
